

Diagnostics Business

Clinical testing, which is essential to healthcare, can be broadly divided into two categories: *in vitro* diagnostics (IVD) that involve the examination of blood, urine, and other samples taken from the body, and *in vivo* diagnostics, which involve direct examination using X-rays or electrocardiograms. Sysmex is developing its diagnostics business, centered on the IVD domain, where we provide medical institutions and other customers with instruments, reagents, and software on a global basis.

IVD is used in a variety of ways. It is used during medical checkups to help prevent disease. IVD is also used in diagnosing diseases, determining treatment methods, measuring the results of drug administration, predicting aggravation, and for post-treatment monitoring. Healthcare without accurate test results is like walking through fog; the path is uncertain. IVD is essential because it allows medical professionals to assess a patient's state of health accurately and swiftly, and to determine optimal treatment methods.


In IVD, within Sysmex's main business fields of hematology, urinalysis, and immunochemistry, testing is conducted to check a patient's physical condition. They are used for a wide range of other purposes, such as disease prevention and early-stage detection through medical checkups, and in treating diseases or managing their prognoses. In fields such as hemostasis and gene testing, tests are performed to measure a person's

physical condition in greater detail and are mainly used in the process of diagnosing and treating diseases.


Medical Robotics Business

In recent years, it has become common to perform minimally invasive laparoscopic surgery to reduce the physical burden on patients. However, this surgery requires a high degree of technical skill, and surgical-support robots that complement these skills are attracting attention from medical workers. Currently, insurance coverage of surgical procedures using these robots has been extended to include urology, gastroenterology, gynecology, and respiratory surgery, and the number of surgeries performed using surgical support robots is gradually increasing. In addition, from the viewpoint of improving access to medical care, such robots are being considered for use with remote medicine. It may not be long before surgeries can be performed with doctors and patients in different locations.


Under these circumstances, Mediaroid Corporation, a joint venture between Sysmex and Kawasaki Heavy Industries, Ltd., developed the first made-in-Japan robotic-assisted surgery system. Sysmex began domestic sales of this system in 2020 as a global exclusive distributor and has since stepped up its market penetration. Internationally, the system obtained regulatory approval in Singapore in 2023, in Malaysia in 2024, and in Vietnam in June 2026. In the EMEA region, as well, Sysmex is pursuing regulatory approval and is actively promoting a global rollout.



What can be determined from samples (blood, urine, and cancer tissue)



Sysmex's Products in Use



1 Commercial Labs

Commercial labs conduct testing for small-scale medical institutions that do not have their own analyzers, as well as handling specialized tests. Large-scale labs, which handle tens of thousands of samples each day, use high-productivity transport systems.

2 Hospitals

In laboratories, our products for testing blood and urine are used for medical checkups and diagnosis of outpatients and inpatients. Operating rooms use our surgical robot systems and employ the OSNA™ method for cancer lymph node metastasis testing.

3 Clinics

Clinics typically use products that are compact and simple.

4 Universities and Research Institutions, etc. (Lab Assay Services)

We are developing a lab assay business, in which we receive samples from medical institutions, test them at our labs and RIKEN GENESIS, and send back the results of protein or gene analyses performed on those samples. In addition to medical institutions, we handle measurements on behalf of universities, research institutes, and pharmaceutical companies, providing information to assist their drug discovery and R&D efforts.

5 Veterinary hospitals

Our products are used in maintaining the health of dogs, cats, and other pets, as well as aquarium and zoo animals.

Primary Products and Services


Diagnostics Business

Hematology and Flow Cytometry (FCM)

For small- and medium-sized institutions, Sysmex offers three-part white blood cell differential models, used for determining basic parameters, as well as five-part white blood cell differential models, used to deliver a high degree of clinical significance and require numerous reagents. In addition, we offer a wide-ranging lineup, including transport systems that can be used for rapid, high-volume testing in large-scale labs. In Japan in 2021, we launched a new five-part white blood cell differential top-end model, as well as a compact model providing three-part white blood cell differentiation. In 2022, we launched sample transportation system modules


equipped with the world's first automated measurement function for quality control materials. Sysmex has been moving forward with the global rollout of its top-end model since 2023. In June 2025, we obtained marketing approval for sales in the United States. We have also entered the FCM testing field, where testing is performed after hematology testing for detailed analyses of leukemia, malignant lymphoma, and similar conditions. We sell sample preparation systems and flow cytometers for research use, achieving full automation of the FCM testing workflow from pretreatment to acquisition of measurement results. Going forward, we will create new value by developing workflows that integrate FCM with hematology testing, among other initiatives.

Product Lineup of Multiparameter Automated Hematology Analyzers



Top-End Model Boosts Efficiency in Laboratory Operations

In 1990, Sysmex developed the world's first fully automated hematology system, which automated everything from the counting of blood cells and the differentiation of white blood cells to smear preparation. This automation not only helped reduce labor costs but also helped reduce the risk of infection during sample handling and prevention of sample mix-ups. The top-end model we launched in 2021 improved processing capacity by 10% compared to the previous model, enhanced the ability to detect abnormal cells, and reduced power consumption by 40% (at maximum output of the transport system). Additionally, by combining peripheral devices based on the "touch-free concept," the system automates tasks such as device startup, quality control, and sample storage and retrieval, significantly minimizing manual work and further enhancing the efficiency of laboratory testing operations.



Note: This is an example of equipment layout.


Hemostasis

Demand for hemostasis testing has increased and grown more diverse due to a rise in thrombotic diseases stemming from lifestyle diseases, as well as to the development of new blood preparations.

Sysmex offers a broad lineup tailored to factors such as facility specialization and testing volume, enabling it to meet diverse testing needs. In 2025, we launched a compact product for the mid- and low-end

markets in Japan first, and in 2026, we expanded our lineup of system products for large-scale facilities in the United States. In addition, we support more efficient laboratory operations across testing fields through the global rollout of system products that integrate hematology and hemostasis testing.


For reagents, in addition to our alliance with Siemens Healthineers, we are developing products with high clinical value through collaboration with Group company HYPHEN BioMed.



Changes to Sales Arrangements with Siemens in Europe and the United States


Since 1995, Sysmex has expanded its business globally through an alliance with Siemens Healthineers (hereinafter, “Siemens”) in the hemostasis field. Previously, the two companies divided sales territories, with Sysmex handling sales in Asia and Siemens handling sales in Europe and the United States.¹ As a result, in Europe and the United States, Sysmex supplied instruments to Siemens but did not conduct direct sales. In April 2024, the two companies entered into a global OEM agreement for hemostasis-related products and eliminated the division of sales territories. This enabled Sysmex to directly sell instruments and reagents under its own brand in European and U.S. markets, approximately doubling the size of the market in which it conducts its own sales. In addition to instruments, Sysmex can now sell high-margin reagents worldwide, contributing to business expansion and improved profitability.

¹ Excluding the United Kingdom



Urinalysis

We developed the world’s first automated urine particle analyzer for urine sediment testing using the flow cytometry method. We are also adding to our portfolio of urine chemistry products by making use of alliances and distribution agreements as we work to expand our lineup in response to diverse urinalysis needs. Furthermore, in 2025, we launched a model for the mid- and low-end markets in Japan, which we plan to roll out globally.



Clinical Chemistry

In April 2026, Sysmex took over JEOL Ltd.’s clinical chemistry business, adding to its portfolio a product lineup in the clinical chemistry field with a high share of the Japanese market. This marked our entry into the clinical chemistry field and we acquired products and technologies featuring reagent miniaturization and high-throughput processing of tests. Going forward, we will expand the reagent business through collaboration with reagent manufacturers while leveraging our global sales network to develop the business.


Immunochemistry

We are working to develop our business in Asia, including Japan, through sales of a fully automated immunoassay system, which performs highly sensitive, high-speed assays on minute sample quantities. In addition to reagents to test for infectious disease and tumor markers, we possess proprietary markers to test for measuring progression of hepatic fibrosis and atopic dermatitis. We are also working to develop reagents for Alzheimer’s disease testing.



Antimicrobial Susceptibility Testing

In 2023, we launched in Europe a system to rapidly detect antimicrobial susceptibility. The system detects the presence or absence of bacteria and assesses the effectiveness of antimicrobials using urine samples from patients suspected of having urinary tract infections. This system delivers test results in as little as 30 minutes, compared with the several days that were previously required. This assists the appropriate use of antimicrobials during initial patient visits at clinics and other primary care settings.



Caresphere™ ICT Solution

We have built a platform for healthcare professionals that integrates and analyzes in real time various types of data managed by testing equipment, laboratory information systems, and other systems. Specifically, external quality control tools and information on equipment operating status support quality control and operational efficiency in laboratories. In addition, instrument maintenance and remote support help reduce the burden on healthcare professionals and improve customer satisfaction.

Cancer Gene Testing

Using our proprietary technology, the OSNA method, we provide a system that automatically and easily detect information to assist in diagnosing lymph node metastasis. We developed a system for cancer genomic profiling that comprehensively analyzes gene mutations in solid tumors, in collaboration with the National Cancer Center Japan. This was the first such system to be covered under Japanese health insurance and is used in clinical settings.

Medical Robotics Business

Robotic-Assisted Surgery System

Compact enough to fit in standard Japanese operating rooms, this system is equipped with user-friendly robot arms and a high-definition 3D videoscope. Furthermore, the system has been designed to be network compatible, to support more accurate treatment by medical workers.




Stakeholder Engagement

Sysmex works alongside its business partners and employees to provide products and services to medical institutions and other customers in an effort to resolve medical and social issues. Going forward, through proactive dialogue with stakeholders, we strive to forge better relations. In addition, by incorporating their expectations and requirements into our business activities, we will enhance the effectiveness of our strategy and strive to realize a sustainable society.

Major Stakeholders

Stakeholders described outside the circle are categorized according to our Shared Values. >>P8



Main Dialogue with Stakeholders

>>Website >Sustainability >Sustainability Management >Stakeholder Engagement


Customers	We engage in ongoing communication through sales and services and support activities, with the aim of instilling confidence in our customers and providing added value that exceeds their expectations. As a result, we earn high marks in customer satisfaction surveys. >>Customer Satisfaction Ratings P18
Employees	To achieve sustainable growth, it is essential that we work on recruiting, developing, and deploying human resources, promoting diversity and inclusion, and creating a workplace that is comfortable, appealing and conducive to work, in line with our Long-Term Corporate Strategy 2033. We have set the engagement score on our corporate culture survey, as one of our sustainability targets, and we are undertaking initiatives to achieve this target. >>Human Capital Strategy P59
Business Partners	We maintain ongoing dialogues to foster an understanding among business partners of Sysmex’s business direction and policies, as well as to build trust-based relationships. For suppliers, we are strengthening communication to realize a circular society, as well as establishing supply chain management in accordance with our procurement policy.
Shareholders	Sysmex recognizes that IR activities are important to achieving sustainable growth and medium- to long-term increases in corporate value. We strive to disclose information proactively and quickly share internally the evaluations and requests that we receive in the course of dialogues with shareholders and investors, and to reflect this information in our management and IR activities. In recent years, we have received valuable suggestions from our investors regarding improvements to capital efficiency and a revision to our rolling mid-term management plan, and we have incorporated this input into our initiatives.
Society	We liaise and engage in dialogue with government agencies and international organizations with a view to the development of healthcare and the realization of a sustainable society. In addition, we communicate with society at large through activities aimed at meeting the needs of communities around the world, based on our Policy on Corporate Citizenship Activities and Philanthropy.

Terminology

Antimicrobial resistance	This phenomenon occurs when living organisms develop a resistance to a drug, whose efficacy is decreased or neutralized as a result. Bacteria that have developed microbial resistance are known as antimicrobial-resistant bacteria.
Commercial lab	A company that specializes in testing operations, performing IVD on behalf of medical institutions, research institutes, and other facilities.
Concentrated reagents	More concentrated than conventional reagents, these reagents are automatically diluted and adjusted by the testing system.
EMEA	Europe, the Middle East, and Africa
Flow Cytometry (FCM)	Method involving the flow dispersion of minute particles and the use of laser light to optically analyze minute flows.
Hematology	The field of <i>in vitro</i> diagnostics that determines whether precise testing is necessary, by analyzing the number, type, and size of red, white, and other blood cells.
<i>in vitro</i> diagnostics (IVD)	In general, IVD refers to the testing of blood, urine and other samples to determine physical condition. IVD may also refer to the domain of laboratory testing in which IVD is performed.
One-Step Nucleic Acid Amplification (OSNA) method	A technique developed by Sysmex that does not require extraction or purification of nucleic acid in the pre-treatment process, enabling one-step amplification.
Panel testing	A test that allows multiple markers to be measured at once. Particularly in genomic medicine, cancer panels are used to analyze the mutation, proliferation, and fusion of multiple genes having diagnostic significance.
Primary care	The initial care provided at clinics or other locations when a patient first falls ill.
Quality control	A management method used to guarantee the values measured by customers’ testing equipment and to confirm that a customer’s equipment is functioning correctly. External quality control is a method under which the same specimens (such as artificially produced blood) are distributed to multiple clinical laboratories, and the measurement results obtained are analyzed using statistical methods, thereby allowing the precision of individual laboratories’ measurement results to be evaluated. The results are provided as feedback to these laboratories, helping to increase the quality of testing.
Reagent	A pharmaceutical product for medical use in laboratory testing, also called an <i>in vitro</i> diagnostic product. It is not used directly on the human body, but on samples of blood or other bodily fluids.
Regulatory approval (manufacturing and marketing approval)	In Japan, the manufacturing and marketing of medical devices and reagents requires approval from the Ministry of Health, Labour and Welfare. Such approval necessitates confirmation of a product’s function and safety. Other countries have their own regulatory procedures: approval from the Food and Drug Administration in the United States, obtaining the CE Mark in Europe (which indicates compliance with the <i>In Vitro</i> Diagnostic Medical Device Directive (IVDD) and the <i>In Vitro</i> Diagnostic Medical Device Regulation (IVDR)), and in China, approval from the National Medical Products Administration (NMPA).
Specimen	Material necessary for testing. May include blood, cerebrospinal fluid, pus, punctured fluid, urine and feces.
Transport system	A system that links multiple analyzers, allowing testing to be automated. In addition to making testing operations more efficient, automation helps reduce the risk of infection when samples are handled manually, and prevents mishandling.
Urine sediment testing	Testing performed to analyze formed elements in the urine, including blood and other cells. Urine chemistry testing, on the other hand, is conducted by using a test paper to analyze for the presence of sugar, protein, or blood cells in urine.

Stock Information (As of the End of Fiscal 2025)

Stock Price Range



Stock Price Movements

Fiscal years	High (Yen)	Low (Yen)	Closing price (Yen)	Volatility (%)
2015	8,640	5,430	7,040	39.2
2016	8,170	6,010	6,750	29.9
2017	9,730	6,080	9,640	24.7
2018	11,110	4,810	6,690	38.7
2019	8,420	5,814	7,846	38.3
2020	13,310	7,024	11,925	27.7
2021	15,725	7,970	8,923	41.6
2022	9,815	7,380	8,643	41.0
2023	10,440	2,637	2,662	29.8
2024	3,236	2,138	2,837	29.0
2025	2,867	1,268	1,369	40.1

Notes: Volatility refers to the annualized standard deviation based on daily closing prices.
Stock splits conducted on April 1, 2024 (1:3). (actually, the end of March)

Total Shareholder Return (TSR)¹ (Annualized Rate)

Investment period	Past 1 Year	Past 3 years		Past 5 years		Past 10 years	
	Cumulative Annual rate	Cumulative	Annual rate	Cumulative	Annual rate	Cumulative	Annual rate
Sysmex	(50.6)	(50.2)	(20.8)	(63.3)	(18.2)	(35.3)	(4.3)
TOPIX	34.6	87.4	23.3	102.2	15.1	228.2	12.6
TOPIX (Electrical equipment)	32.8	75.7	20.7	85.1	13.1	333.5	15.8


¹ TSR: Total shareholder return, including capital gains and dividends
• Prepared by Sysmex based on data from Nikkei NEEDSFinancial QUEST
• Base date of March 31, 2026
• TSR calculated on the assumption that dividends are reinvested in shares

Principal Shareholders (Top 10)


Shareholders	Number of shares held (Thousands)	Percentage of shareholding (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)	72,152	11.52
Nakatani Foundation	38,692	6.18
The Kobe Yamabuki Foundation	36,000	5.75
Nakatani Kosan, Ltd.	34,341	5.48
Custody Bank of Japan, Ltd. (Trust Account)	29,830	4.76
Kazuko Ietsugu	20,909	3.34
Taeko Wada	19,489	3.11
STATE STREET BANK AND TRUST COMPANY 505001	16,749	2.67
Rusoru, Ltd.	14,250	2.27
NORTHERN TRUST CO.(AVFC) SUB A/C AMERICAN CLIENTS	9,781	1.56

Note: Percentage of shareholding excludes treasury stock (3,039,291 shares).

Distribution of Shares by Number of Shares Held



Composition of Shareholders



Corporate Information (As of the End of Fiscal 2025)

Sysmex Corporation

Established	February 20, 1968
Head Office	1-5-1, Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan
Inquiries	IR Department: TEL: +81-78-265-0500
Website	https://www.sysmex.co.jp/en/
Number of Employees	11,731 (consolidated basis) (including part-time employees and others)
Fiscal Year	April 1–March 31
Shareholders' Meeting	June
Number of Shares Authorized	1,796,064,000 shares
Number of Shares Issued	629,480,076 shares
Paid-in Capital	¥14,898.5 million
Stock Listings	Tokyo Stock Exchange, Prime Market
Ticker Code	6869
Transfer Agent	Mitsubishi UFJ Trust and Banking Corporation
Independent Auditor	Deloitte Touche Tohmatsu LLC
Rating	AA- (Rating and Investment Information, Inc. (R&I))
Major Indexes	Dow Jones Best-in-Class World Index Dow Jones Best-in-Class Asia Pacific Index FTSE4Good Index Series FTSE Blossom Japan Index FTSE Blossom Japan Sector Relative Index Morningstar Japan ex-REIT Gender Diversity Tilt Index MSCI ESG Selection Indexes MSCI Japan ESG Select Leaders Index MSCI Japan Empowering Women Index (WIN) S&P/JPX Carbon Efficient Index ISS ESG "Prime" Status iSTOXX MUTB Japan Platinum Career 150 Index



2026 CONSTITUENT MSCI NIHONKABU ESG SELECT LEADERS INDEX

2026 CONSTITUENT MSCI JAPAN EMPOWERING WOMEN INDEX (WIN)



>>Website >Sustainability >External Evaluation